New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
08:16 EDTSNY, REGNSanofi and Regeneron report positive results from Phase 2 study with alirocumab
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) said the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 or proprotein convertase subtilisin/kexin type 9, in Japanese patients met its primary endpoint. The results demonstrated that the mean low-density lipoprotein-cholesterol percentage reduction from baseline to week 12, the primary efficacy endpoint of the study, was significantly greater in patients randomized to receive one of three doses of alirocumab administered every other week -- 150 milligrams, or mg, 75 mg, and 50 mg, in combination with statin therapy, compared to patients receiving placebo.
News For SNY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTREGNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use